Medical devices continue to be a strong growth driver for Abbott, as the company battles its ongoing sales slump in ...

Abbott narrowly missed analysts’ expectations of $11.4bn for Q3 2025, with diminished Covid-19 test demand and China ...

Abbott missed analysts' third-quarter revenue estimates on Wednesday, as weakness in its diagnostics and nutrition businesses ...

The company reported third-quarter sales of $11.37 billion, slightly missing the consensus of $11.40 billion. The U.S.

Abbott missed analysts' estimates for third-quarter revenue on Wednesday, as weakness in its diagnostics and nutritional ...

Abbott Labs reported 6.9% sales growth in Q3 2025, led by medical devices and nutrition, while reaffirming full-year guidance ...

Abbott stock fell as Q3 sales missed estimates and 2025 earnings guidance was narrowed despite solid growth in medical ...

Lab personnel say worries are mounting over the safety of a rapid coronavirus test by Abbott Laboratories that President Donald Trump has repeatedly lauded ― particularly, the risk of infection to ...

Cleared by the FDA in 2024, the test gained real-world traction in 2025 when it was incorporated into a new global framework ...

Abbott’s i-STAT Traumatic Brain Injury (TBI) test only takes about 15 minutes to look for signs of brain injury by checking ...